Agree Fortuno, the Placebo arm of the Trials will be a "bear" to enroll. One would think morbidity and mortality rates of patients who have not been treated with Leronlimab in the past would suffice as a comparison cohort for the Treatment arm. IMO, insisting on a double blind and placebo arm is beyond burdensome and are not necessary to establish treatment efficacy. While I am not a bioscientist or a medical researcher, I have enough professional experience and education to recognize an impractical Trial Protocol, and that is stating the case mildly.